Valeant 2014 guidance in line with the Street

Valeant Pharmaceuticals (VRX +2.3%) forecasts 2014 adjusted EPS of $8.25-8.75, in line with consensus of $8.71.

Revenues are pegged at $8.2-8.6B vs $8.28B.

Expects growth across all its business units.

Q4 EPS seen at $2.05-2.10 and revenue at $2B, unchanged from prior guidance.

Valeant's plans for 2014 include: achieving annual run-rate synergies of over $900M from the acquisition of Bausch + Lomb; closing at least one significant deal; launching several products; and cutting its leverage ratio to below 4x adjusted pro forma EBITDA. (Presentation)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs